Literature DB >> 31123091

Optimal Use of Biomarkers for Chronic Kidney Disease.

W Greg Miller1, Lorin M Bachmann2, Joris R Delanghe3, Lesley A Inker4, Graham R D Jones5,6, Joseph A Vassalotti7,8.   

Abstract

Entities:  

Year:  2019        PMID： 31123091     DOI： 10.1373/clinchem.2018.299073

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  5 in total

1.  Kidney Diseases: The Age of Molecular Markers.

Authors:  Glaucia Luciano da Veiga; Beatriz da Costa Aguiar Alves; Matheus Moreira Perez; Joyce Regina Raimundo; Jéssica Freitas de Araújo Encinas; Neif Murad; Fernando Luiz Affonso Fonseca
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Integrating CKD Into US Primary Care: Bridging the Knowledge and Implementation Gaps.

Authors:  Joseph A Vassalotti; Suelyn C Boucree
Journal:  Kidney Int Rep       Date:  2022-02-04

3.  Combined Albuminuria and Estimated GFR Laboratory Reporting Affects Primary Care Management of CKD.

Authors:  Joseph A Vassalotti; Sumeska Thavarajah
Journal:  Kidney Med       Date:  2020-05-08

4.  Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations.

Authors:  Nikita Stempniewicz; Joseph A Vassalotti; John K Cuddeback; Elizabeth Ciemins; Amy Storfer-Isser; Yingying Sang; Kunihiro Matsushita; Shoshana H Ballew; Alex R Chang; Andrew S Levey; Robert A Bailey; Jesse Fishman; Josef Coresh
Journal:  Diabetes Care       Date:  2021-07-07       Impact factor: 17.152

5.  Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database.

Authors:  David Alfego; Jennifer Ennis; Barbara Gillespie; Mary Jane Lewis; Elizabeth Montgomery; Silvia Ferrè; Joseph A Vassalotti; Stanley Letovsky
Journal:  Diabetes Care       Date:  2021-08-05       Impact factor: 19.112
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.